Reuters (02/17/12) Yukhananov, Anna; Basu, Anand
The FDA has approved Corcept Therapeutics' drug Korlym for the treatment of Cushing's Syndrome, a hormonal disease. Cushing's affects around 20,000 people mainly between 20 and 50 and causes excessively high production of cortisol which can cause high blood pressure, upper body obesity, and diabetes. Generically known as mifepristone, Korlym was approved as an orphan drug, but will carry a warning label letting doctors and patients know that the therapy will terminate a pregnancy. This is the first drug approved to treat Cushing's in the U.S., though Novartis' Signifor treatment was recently approved in Europe.

Read the complete article